Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: cav who wrote (1021)	7/21/1998 11:45:00 AM
From: John Metcalf	Respond to of 10280

Cav, try this link for insider activity: biz.yahoo.com No sales in the last year, though some shares were given as gifts. You might evaluate management by going back a few years through 10-K's and comparing subsequent events to their announced intentions. My evaluation is that they have identified great targets, and have hit them in rapid succession. This is particularly impressive because they also target the preferred licensee for each product, and have been strong enough to sign each deal with that particular licensee. Management has amassed sufficient cash to sustain Sepracor to profitability. Each deal appears stronger than the last, with SEPR retaining more rights to the product. There are also intimations that financial terms of licenses continually improve.